Taysha Gene Therapies Inc [NASDAQ: TSHA] closed the trading session at $3.62.
The stocks have a year to date performance of 104.52 percent and weekly performance of 11.73 percent. The stock has been moved at 105.68 percent over the last six months. The stock has performed 40.31 percent around the most recent 30 days and changed 20.67 percent over the most recent 3-months.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
If compared to the average trading volume of 2.40M shares, TSHA reached to a volume of 5807325 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Taysha Gene Therapies Inc [TSHA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for TSHA shares is $6.95 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on TSHA stock is a recommendation set at 1.10. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Piper Sandler have made an estimate for Taysha Gene Therapies Inc shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on April 09, 2024. While these analysts kept the previous recommendation, Jefferies dropped their target price from $14 to $1.50. The new note on the price target was released on February 01, 2023, representing the official price target for Taysha Gene Therapies Inc stock. Previously, the target price had yet another drop from $23 to $3, while Morgan Stanley kept a Equal-Weight rating on TSHA stock. On November 09, 2022, analysts decreased their price target for TSHA shares from 16 to 3.
The Average True Range (ATR) for Taysha Gene Therapies Inc is set at 0.26, with the Price to Sales ratio for TSHA stock in the period of the last 12 months amounting to 47.81. The Price to Book ratio for the last quarter was 12.57, with the Price to Cash per share for the same quarter was set at 0.67.
TSHA stock trade performance evaluation
Taysha Gene Therapies Inc [TSHA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 11.73. With this latest performance, TSHA shares gained by 40.31% in over the last four-week period, additionally plugging by 105.68% over the last 6 months – not to mention a rise of 382.67% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for TSHA stock in for the last two-week period is set at 70.38, with the RSI for the last a single of trading hit 76.11, and the three-weeks RSI is set at 66.14 for Taysha Gene Therapies Inc [TSHA]. The present Moving Average for the last 50 days of trading for this stock 2.78, while it was recorded at 3.32 for the last single week of trading, and 2.34 for the last 200 days.
Taysha Gene Therapies Inc [TSHA]: An insightful look at the core fundamentals
Taysha Gene Therapies Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.36 and a Current Ratio set at 3.36.
Taysha Gene Therapies Inc [TSHA]: Institutional Ownership
The top three institutional holders of TSHA stocks are: VANGUARD GROUP INC with ownership of 1.32 billion shares, which is approximately 8.4983%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $200.69 billion in TSHA stocks shares; and BERKSHIRE HATHAWAY INC, currently with $174.35 billion in TSHA stock with ownership which is approximately 5.8386%.
